Antibody-Based Cancer Immunotherapy - Episode 17

Optimizing Checkpoint Inhibition in NSCLC

For High-Definition, Click

The response rate with PD-1 inhibition in non-small cell lung cancer (NSCLC) is approximately 20% to 40%, depending on PD-L1 status. For patients who do not respond to single-agent PD-1 inhibition, combination strategies could be utilized to further improve outcomes.

The Lung-MAP study is currently assessing various treatment options based on molecular characteristics. In addition to immunotherapy, this study will also assess platinum-based chemotherapy.

View the video, to hear the discussion.